Phenotypic and genotypic Helicobacter pylori clarithromycin resistance and therapeutic outcome: benefits and limits | Zendy

Vincenzo De Francesco | Zendy; Angelo Zullo | Zendy; Enzo Ierardi | Zendy; Floriana Giorgio | Zendy; Federico Perna | Zendy; Cesare Hassan | Zendy; S. Morini | Zendy; C. Pañella | Zendy; D. Vaira | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Phenotypic and genotypic Helicobacter pylori clarithromycin resistance and therapeutic outcome: benefits and limits

Author(s) -

Vincenzo De Francesco,

Angelo Zullo,

Enzo Ierardi,

Floriana Giorgio,

Federico Perna,

Cesare Hassan,

S. Morini,

C. Pañella,

D. Vaira

Publication year - 2009

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkp445

Subject(s) - clarithromycin , helicobacter pylori , genotype , concordance , phenotype , antibiotic resistance , drug resistance , medicine , biology , immunology , antibiotics , microbiology and biotechnology , genetics , gene

Primary clarithromycin resistance is increasing worldwide, and it has been regarded as the main factor reducing the efficacy of Helicobacter pylori therapy. However, the clinical consequence of either phenotypic or genotypic resistance still remains unclear. This study aimed to evaluate: (i) the concordance between phenotypic (culture) and genotypic (real-time PCR) tests in assessing primary clarithromycin resistance; and (ii) the role of both in therapeutic outcome.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research